All | dcSSc | lcSSc | p Value | |
---|---|---|---|---|
N | 50 | 39 | 11 | |
Sex, F:M | 45:5 | 34:5 | 11:0 | 0.079 |
Mean ± SD age, years | 48.7 ± 10.3 | 50.1±10.4 | 43.9±8.6 | 0.573 |
Mean ± SD duration of disease, years | ||||
- duration from onset | 7.1±4.4 | 6.8±4.6 | 8.1±4.0 | 0.408 |
- duration from Dx | 5.8±4.4 | 5.6±4.6 | 6.8±3.6 | 0.429 |
Telangiectasia (%) | 14 | 15.4 | 9.1 | 1.0 |
Pulmonary fibrosis (%) | 68 | 66.7 | 72.7 | 1.0 |
Poikiloderma (%) | 50 | 56.4 | 27.3 | 0.171 |
Pulmonary hypertensiona(%) | 12.5 | 12.8 | 1.1 | 0.578 |
Sclerodactyly (%) | 84 | 89.7 | 63.6 | 0.059 |
Digital pitting scar (%) | 72 | 84.6 | 27.3 | 0.001 |
Dysphagia (%) | 38 | 41.0 | 27.3 | 0.498 |
Gastroesophageal reflux disease (%) | 34 | 28.2 | 54.5 | 0.151 |
Myositis (%) | 10 | 7.7 | 18.2 | 0.301 |
Arthritis (%) | 22 | 17.9 | 36.4 | 0.229 |
Anti-nuclear antibody (ANA) (%) | 100 | 100 | 100 | 1.0 |
Anti-Scl70 (%) | 68 | 84.6 | 9.1 | <0.001 |
Anti-centromere (%) | 2 | 0 | 9.1 | 0.220 |
Anti-RNP (%) | 32 | 23.1 | 63.6 | 0.024 |
Anti-SSA (%) | 34 | 30.8 | 45.5 | 0.475 |
Anti-SSB (%) | 6 | 5.1 | 9.1 | 0.534 |